SynthesisFrontiers in medicine2026
Prevalence and factors associated with pulmonary hypertension in patients undergoing maintenance hemodialysis: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Maintenance hemodialysis (MHD) is a primary treatment for end-stage kidney disease (ESKD). Patients on long-term MHD frequently develop cardiovascular complications, with pulmonary hypertension (PH) prevalence reported as high as 47%. Due to small sample sizes and inconsistent findings, associated factors for PH in MHD patients remain unclear. Objective: To evaluate the prevalence and associated factors of PH in MHD patients. Methods: We systematically searched literature on PH risk factors in MHD patients across PubMed, Web of Science, CINAHL, Cochrane Library, Embase, CNKI, CBM, Wanfang, and VIP (inception to April 20, 2026). Two reviewers independently screened and extracted data. Data were synthesized using Stata 18.0. Results: Thirty-nine studies comprising 6,633 subjects were included, of whom 3,930 were males and 2,703 were females. The pooled PH prevalence was 37% (95% CI: 0.32-0.42). Multiple factors were significantly associated with PH ( Conclusion: The high PH prevalence in MHD patients, influenced by diverse factors, calls for enhanced clinical vigilance. Management should focus on early identification of high-risk patients, strengthened volume management, inflammation control, and cardiac monitoring. This approach is essential to lower PH risk and improve cardiovascular prognosis. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261378052.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.